CAR-T therapy for autoimmune disease after prior treatment
Part of Blood & lymphatic, Bones, joints & muscles, Brain & nervous system, Eyes & vision, Immune system & allergy, Mouth & dental, Skin clinical trials.
This trial tests a new CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells. It is for people with certain autoimmune diseases (like lupus or scleroderma) that have not responded well to standard treatments or have relapsed after prior cell therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old.
- You have tried a CD19 or BCMA targeted cell therapy before and it stopped working or wore off at least 6 months ago.
- You have one of these autoimmune diseases that is active and not well controlled: lupus, scleroderma with lung involvement, inflammatory myositis, Sjogren's syndrome, autoimmune hemolytic anemia, or multiple sclerosis.
- Your organs (like heart, lungs, liver, kidneys) are working well enough.
- You are not pregnant and agree to use birth control during and for 2 years after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells (called CAR-T cells) designed to target and attack cells that cause autoimmune diseases. It is for people with lupus, Sjögren's syndrome, inflammatory myopathy, scleroderma, Behcet's disease, ANCA-associated vasculitis, IgG4-related disease, antiphospholipid syndrome, or thrombotic thrombocytopenic purpura who have not improved with standard therapies.
This trial tests a new treatment called CAR-T cells that target two proteins (BCMA and CD19) on immune cells. It is for people with certain autoimmune diseases that have not improved with standard treatments.
This trial tests a special immune cell therapy (CAR-T cells targeting CD19 and BCMA) for people with lupus nephritis, systemic sclerosis, or Sjögren's-related lung blood vessel disease that hasn't improved with usual treatments. The goal is to see if this one-time cell infusion can calm the overactive immune system and improve symptoms.
This trial tests a personalized cell therapy (CAR-T) that targets a protein called CD19 on immune cells. It's for people with certain autoimmune diseases like lupus or scleroderma that are still active despite standard treatments. The goal is to see if this therapy can help control the disease when other options haven't worked.
This trial tests a special immune cell therapy (CAR T cells) for people with severe lupus, Sjogren's syndrome, systemic sclerosis, and other autoimmune conditions that haven't improved with standard treatments. The therapy is designed to target and reset the immune system.
This early-phase trial tests a new CAR-T cell therapy that targets CD19 or both CD19 and BCMA to treat several autoimmune diseases like lupus, scleroderma, and vasculitis. It aims to calm the overactive immune system with a single infusion of your own engineered cells.
Hear when a new Relapsed/Refractory Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.